Navigation Links
Hagens Berman Sobol Shapiro Investigating CellCyte
Date:1/9/2008

SEATTLE, Jan 9 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP (http://www.hbsslaw.com/cellcyte.htm) today announced it is investigating the business practices of CellCyte (OTC Bulletin Board: CCYG) for potential violations of securities laws.

The investigation comes after CellCyte's shares plunged 55 percent after news reports detailed alleged discrepancies in CellCyte CEO Gary Reys' educational and professional credentials.

CellCyte's stock dropped after the company made changes to its Web site concerning Reys' claims to have attended University of Washington and to be a certified public accountant. Media reports also call into question other claims made by Reys concerning his role in other business ventures.

According to published media reports, the changes were prompted by calls from Seattle media questioning the veracity of Reys' claims.

If you are an investor in CellCyte, have information concerning this investigation or if you have any questions concerning CellCyte's actions, please contact plaintiff's counsel at 206-623-7292 or e-mail the law firm at info@hbsslaw.com. You can view additional materials on this investigation at http://www.hbsslaw.com/cellcyte.htm.

Hagens Berman Sobol Shapiro, a law firm with offices in Seattle, San Francisco, Los Angeles, Boston, Chicago and Phoenix, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. The Hagens Berman Web site (http://www.hbsslaw.com) has more information about the firm.

Contact: Hagens Berman Sobol Shapiro LLP

206-623-7292

info@hbsslaw.com

http://www.hbsslaw.com


'/>"/>
SOURCE Hagens Berman Sobol Shapiro LLP
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
4. CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... ... May 18, 2016 , ... Every day, more than ... asthma complications.* Costing more than $56 billion in direct costs annually, asthma remains ... too many, the suffering associated with uncontrolled asthma can be overwhelmingly disproportionate and ...
(Date:5/17/2016)... ... 2016 , ... DryLet, LLC, a biotechnology company providing an ... be showcasing ManureMagic™ at booth V1061 at the World Pork Expo, June 8-10 ... last year and more recently made news as the results were released from ...
(Date:5/17/2016)... , May 17, 2016 ... in Basel, Switzerland announced ... inhibitor of P38 mitogen-activated protein kinase. ... Strekin will build the necessary research foundation ... in which MAP Kinases play fundamental roles. Pamapimod ...
(Date:5/17/2016)... ... May 17, 2016 , ... New tests that go ... country promising more specific information that both the patient and doctor want and need ... tests, presented at the American Urological Association’s annual meeting in San Diego, involve using ...
Breaking Biology Technology:
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):